Track papers across labs, topics, and trends.
Search papers, labs, and topics across Lattice.
This paper introduces TrialGPT 2.0, an AI-assisted clinical trial recommendation system that not only assesses patient eligibility but also prioritizes trials based on clinical needs and workflow considerations. Evaluated in both retrospective and prospective multicenter settings, the system achieved a 91% success rate in retrieving clinician-recommended trials while significantly reducing screening time by 55%. The deployment of TrialGPT 2.0 expanded patient access to clinical trials by 90.9%, highlighting its potential to enhance recruitment in oncology research.
TrialGPT 2.0 not only streamlines trial matching but also uncovers nearly 91% of missed opportunities for patient enrollment in clinical trials.
Clinical trials are essential for advancing cancer care and drug development, but many fail because of insufficient patient enrollment. While there is growing interest in using AI to support patient recruitment, existing systems largely perform eligibility assessment alone and have rarely been evaluated in real-world oncology workflows. Here we present TrialGPT 2.0, an AI-assisted clinical trial recommendation system designed for real-world deployment. Rather than asking only whether a patient may qualify, the system also assesses which trials warrant further consideration given the patient's current clinical needs and local workflow priorities, and provides structured, inspectable explanations for expert review. Importantly, we evaluated TrialGPT 2.0 retrospectively and prospectively across multiple oncology-focused settings, spanning government, academic cancer-center, patient-advocacy, and NIH referral workflows. In retrospective multicenter cohorts comprising 288 cases, TrialGPT 2.0 retrieved at least one clinician-recommended trial in its top 10 recommendations for approximately 91% of cases while reducing clinician screening time by 55.0%. In a six-month prospective evaluation embedded in an active precision oncology tumor board, TrialGPT 2.0 contributed additional trial opportunities missed by the routine workflow, expanding patient access to clinical trial participation by 90.9%. To support scientific reproducibility, we also introduce NIH-TrialBench, a clinician-authored dataset comprising 126 diverse synthetic patient vignettes and matching scenarios from 11 NIH Institutes and Centers. Together, these results support the value of AI to assist clinical trial matching by improving clinician efficiency and identifying frequently overlooked trial opportunities, ultimately helping to expand and accelerate accrual to cancer trials.